Clinical Trial

Assessment of QoL and Outcomes with SBRT for RCC

Study Description

Assessment of QoL and Outcomes With SBRT for RCC

Stereotactic body radiotherapy (SBRT) is an emerging radiotherapy technique that precisely delivers high doses of radiation to tumours. It has been investigated as definitive treatment for an increasing variety of primary tumours including lung, liver, prostate, and now renal cell carcinoma (RCC). The principal aims of this study are to prospectively assess quality of life (QoL) and oncologic outcomes in non-surgical patients who receive SBRT for the treatment of RCC.


Locations Selected Location


No pharmaceutical medication involved No pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Radiation - SBRT

35-40 Gy delivered in 5 fractions

Additional Information

Official Study Title

Assessment of Quality of Life and Outcomes in Patients Treated With Stereotactic Body Radiation Therapy (SBRT) for Primary Renal Cell Carcinoma (RCC) - AQuOS-RCC

Clinical Trial ID


ParticipAid ID